A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Phase 2

Recruiting

• Conditions: Major Depressive Disorder
• Interventions: Drug: SP-624; Drug: Placebo

• Registration Number: NCT06254612
• Lead Sponsor: Sirtsei Pharmaceuticals, Inc.

Brief Summary

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-02-02
• Study First Submitted QC: 2024-02-02
• Study First Posted: 2024-02-12
• Study Start: 2024-03-25
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-11
• Last Update Posted: 2025-07-14
• Primary Completion: 2025-09-30
• Study Completion: 2025-11-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 456

Inclusion Criteria

• Males and females, aged 18 to 65 years, inclusive.
• Meet DSM-5 criteria for moderate to severe MDD, as confirmed by the Mini International Neuropsychiatric Interview (MINI).
• In generally good physical health, in the opinion of the Investigator.
• Body mass index (BMI) must be ≥ 18 and ≤ 45 kg/m2.

Key

Exclusion Criteria

• Female who is pregnant, breastfeeding, or less than 6 months postpartum at screen.
• A history of or current DSM-5 diagnosis of MDD with psychotic features, any schizophrenia spectrum and other psychotic disorders, bipolar disorder, or personality disorder.
• Presence or history of any known clinically significant cardiovascular disorders including, but not limited to: coronary artery disease, heart failure, valvular heart disease, cardiomyopathies, myocardial infarction, chamber enlargement or hypertrophy, or orthostatic hypotension.
• Presence of uncontrolled hypertension, defined as consistent sitting systolic blood pressure (SBP) >160 mmHg or consistent sitting diastolic blood pressure (DBP) >95 mmHg despite present therapy.
• Screening laboratory value(s) outside the laboratory reference range that are considered to be clinically significant by the Investigator (clinical chemistry, hematology, thyroid function, and urinalysis).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SP-624	SP-624	Participants to receive two 10 mg capsules of SP-624 once daily for a total daily dose of 20 mg
Placebo	Placebo	Participant to receive 2 matching placebo capsules once daily

Primary Outcome Measures

Name	Time	Method
Change from Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score.	Baseline to Week 4	The MADRS is a 10-item depression rating scale used to assess the severity of depression. Individual items are scored on a 7-point scale (0 to 6). The toal score is the sum of individual items, ranging from 0 to 60; where a higher score indicates more depression.

Secondary Outcome Measures

Name	Time	Method
Change from Baseline in the Clinical Global Impression - Severity (CGI-S) score.	Baseline to Weeks 1-4 and 1- and 2- Week Follow-up	The CGI-S is a 7-point scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. A score of 1 represents "normal" and 7 represents "most extremely ill".
Incidence rates of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to withdrawal from study.	Baseline to Weeks 1-4 and 1- and 2- Week Follow up
Change from Baseline in Quick Inventory of Depressive Symptomology-Self-Report (QIDS-SR) total score.	Baseline to Weeks 1-4 and 1- and 2- Week Follow-up	The QIDS-SR is a 16-item self-reported scale where each item has a 4-point scale where 0 represents least impact scores while 3 represents greatest impact scores. Some questions are linked. The total score ranges from 0 to 27 where a higher score indicates more depression.
Change from Baseline in Symbol Digit Modalities Test (SDMT) score.	Baseline to Weeks 2 and 4	The SDMT is an assessment of complex scanning and visual tracking requiring elements of attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The SDMT measures the time to pair abstract symbols with specific numbers. The number of correct substitutions within 90 seconds is recorded and the total score is derived from the total number of correct responses with a minimum possible score of 0 and maximum of 110 where high scores indicate better outcome.
Change from Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score.	Baseline to Weeks 1-3 and 1- and 2- Week Follow-up	The MADRS is a 10-item depression rating scale used to assess the severity of depression. Individual items are scored on a 7-point scale (0 to 6). The toal score is the sum of individual items, ranging from 0 to 60; where a higher score indicates more depression.
Change from Baseline in 17-item-Hamilton Depression Rating Scale (HAM-D-17) total score.	Baseline to Weeks 2 and 4	The 17-item HAM-D is used to assess the severity of depression. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=No difficulty/absent and 4=most severe. The total score is the sum of individual items, ranging from 0 to 52; where a higher score indicates more depression.
Change from Baseline in Sheehan Disability Scale (SDS) total score.	Baseline to Weeks 2 and 4	The SDS is a 3-part scale that measures the degree of disruption on work, social and family life using an 11-point scale where 0 represents "no disruption" and 10 represents "extreme disruption". In addition to the 11-point scale, participants are asked to indicate the number of days in the past week that were "lost" and numbers of days that were "underproductive". The results of these questions have a range from 0 to 7. A total global functioning impairment score can be utilized by summing the scores from work, social and family life scales for a value range from 0 to 30.

Trial Locations

Locations (40)

Noble Clinical Research; 🇺🇸 Tucson, Arizona, United States

IMA Clinical Research; 🇺🇸 Albuquerque, New Mexico, United States

SanRo Clinical Research Group; 🇺🇸 Bryant, Arkansas, United States

Clinical Innovations; 🇺🇸 Bellflower, California, United States

Sun Valley Research Center; 🇺🇸 Imperial, California, United States

Sunwise Clinical Research; 🇺🇸 Lafayette, California, United States

Synergy San Diego; 🇺🇸 Lemon Grove, California, United States

Excell Research; 🇺🇸 Oceanside, California, United States

CiTrials; 🇺🇸 Riverside, California, United States

Collaborative Neuroscience Research; 🇺🇸 Torrance, California, United States

Scroll for more (30 remaining)